Organization
Stanford Univ., Palo Alto
2 abstracts
Abstract
12-WEEK RESULTS OF A PHASE 2B DOSE-RANGING STUDY OF LY3009104 (INCB028050), AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS Org: Mount Sinai Hospital, Toronto, Canada, Univ. of Oxford, Oxford, United Kingdom, Stanford Univ., Palo Alto, Eli Lilly & Co, Indianapolis, Incyte Corp., Wilmington, United States,
Abstract
BELIMUMAB (FULLY HUMAN MONOCLONAL ANTIBODY TO BLYS) IMPROVED OR STABILIZED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY AND REDUCED FLARE RATE DURING 3 YEARS OF THERAPYOrg: NSLIJHS, Lake Success, NY, Lake Success, NY, JHU, Baltimore, Cedars-Sinai Comprehensive Cancer Center,